New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Check below for free stories on FDX;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 17, 2014
07:31 EDTFDXFedEx reports Q1 EPS $2.10, consensus $1.96
Reports Q1 revenue $11.7B, consensus $11.48B. “FedEx Corp. is off to an outstanding start in fiscal 2015, thanks to very strong performance at FedEx Ground, solid volume and revenue increases at FedEx Freight and healthy growth in U.S. domestic volume at FedEx Express,” said Frederick W. Smith, FedEx Corp. chairman, president and CEO. “More customers are relying on FedEx because they appreciate the competitive advantages provided by our broad portfolio of solutions.”
September 16, 2014
17:02 EDTFDXFedEx subsidiaries to increase shipping rates in 2015
Subscribe for More Information
16:00 EDTFDXFedEx technical comments ahead of results
Shares have outperformed in the last three months, trading up over 10%. The trading range in the same period has been contained between $146 at the low and $155 at the top, the latter being close to the life high. On stronger than expected news, the shares could easily top life highs, opening up a range of $156 to $165 depending on the degree of positive surprise. Without resistance, there may be room for an upside surprise in price. If the shares break the low at $146, the technical picture for the stock could change considerably. A break below $145 would put the current uptrend in jeopardy. Additional supports below are at $140.27 and $135.49 on an extreme move lower.
15:14 EDTFDXNotable companies reporting before tomorrow's open
Subscribe for More Information
14:39 EDTFDXFedEx September 155 straddle priced for 3% move into Q1
Subscribe for More Information
12:35 EDTLLYDenovo Biopharma acquires late-stage oncology drug enzastaurin from Eli Lilly
Subscribe for More Information
07:31 EDTLLYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:02 EDTLLYEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTLLYAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
September 15, 2014
08:33 EDTFDXFedEx September volatility elevated into Q1 and outlook
FedEx September call option implied volatility is at 34, October is at 19, January is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q1 results before the market open on September 17.
07:40 EDTFDXFactors working in FedEx favor in first quarter of 'turnaround' year, WSJ says
Subscribe for More Information
07:32 EDTFDXFedEx should report solid Q1 results, says Oppenheimer
Oppenheimer raised its Q1 estimates for FedEx slightly above consensus levels, as the firm expects the company to benefit from strong consumer e-commerce sales, improving B2B package volumes, and continued margin expansion in Express. The firm raised its price target on the name to $172 from $168 and keeps an Outperform rating on the stock.
07:26 EDTLLYPiper Jaffray to hold a conference
Subscribe for More Information
September 12, 2014
08:02 EDTLLYEli Lilly announces Cyramza Phase III cancer trial meets primary endpoint
Subscribe for More Information
08:01 EDTLLYEli Lilly announces Cyramza Phase III cancer trial meets primary endpoint
Eli Lilly announced that the RAISE trial, a Phase III study of ramucirumab in combination with chemotherapy in patients with metastatic colorectal cancer, met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab plus FOLFIRI to placebo plus FOLFIRI as a second-line treatment in patients with mCRC after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine in the first-line setting. RAISE showed a statistically significant improvement in overall survival in patients treated with ramucirumab plus FOLFIRI compared to placebo plus FOLFIRI. The study also showed a statistically significant improvement in progression-free survival in the ramucirumab-plus-FOLFIRI arm compared to the placebo-plus-FOLFIRI arm.
07:53 EDTFDXUPS squeezed by growth of e-commerce, power of Amazon, WSJ says
Subscribe for More Information
September 10, 2014
07:04 EDTLLYEU grants marketing authorization for Eli Lilly's insulin glargine product
The European Commission granted marketing authorization for Eli Lilly and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim alliance. It received a positive recommendation from the Committee for Medicinal Products for Human Use on June 26. The marketing authorisation for the alliance's insulin glargine product is based upon a comprehensive clinical data program. The application included results from pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in patients with type 1 and type 2 diabetes.
September 9, 2014
14:43 EDTFDXFedEx September volatility elevated into Q1 and outlook
Subscribe for More Information
September 8, 2014
07:15 EDTLLYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:01 EDTLLYIgnyta names Robert Wild as Chief Scientific Officer
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use